1. Home
  2. BCDA vs NIVF Comparison

BCDA vs NIVF Comparison

Compare BCDA & NIVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • NIVF
  • Stock Information
  • Founded
  • BCDA N/A
  • NIVF 2011
  • Country
  • BCDA United States
  • NIVF Thailand
  • Employees
  • BCDA N/A
  • NIVF N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • NIVF
  • Sector
  • BCDA Health Care
  • NIVF
  • Exchange
  • BCDA Nasdaq
  • NIVF NYSE
  • Market Cap
  • BCDA 9.4M
  • NIVF 9.8M
  • IPO Year
  • BCDA N/A
  • NIVF N/A
  • Fundamental
  • Price
  • BCDA $3.25
  • NIVF $1.02
  • Analyst Decision
  • BCDA Strong Buy
  • NIVF
  • Analyst Count
  • BCDA 1
  • NIVF 0
  • Target Price
  • BCDA $60.00
  • NIVF N/A
  • AVG Volume (30 Days)
  • BCDA 56.4K
  • NIVF 337.9K
  • Earning Date
  • BCDA 08-07-2024
  • NIVF 08-16-2024
  • Dividend Yield
  • BCDA N/A
  • NIVF N/A
  • EPS Growth
  • BCDA N/A
  • NIVF N/A
  • EPS
  • BCDA N/A
  • NIVF N/A
  • Revenue
  • BCDA $468,000.00
  • NIVF N/A
  • Revenue This Year
  • BCDA N/A
  • NIVF N/A
  • Revenue Next Year
  • BCDA $436.41
  • NIVF N/A
  • P/E Ratio
  • BCDA N/A
  • NIVF N/A
  • Revenue Growth
  • BCDA N/A
  • NIVF N/A
  • 52 Week Low
  • BCDA $2.62
  • NIVF $0.64
  • 52 Week High
  • BCDA $39.60
  • NIVF $17.24
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 42.62
  • NIVF 44.49
  • Support Level
  • BCDA $2.62
  • NIVF $0.90
  • Resistance Level
  • BCDA $3.38
  • NIVF $1.25
  • Average True Range (ATR)
  • BCDA 0.30
  • NIVF 0.09
  • MACD
  • BCDA 0.11
  • NIVF 0.04
  • Stochastic Oscillator
  • BCDA 82.88
  • NIVF 34.29

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About NIVF NEWGENIVF GROUP LIMITED

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Share on Social Networks: